PC
AERI

PointState Capital’s Aerie Pharmaceuticals AERI Stock Holding History

PointState Capital’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-281,600
Closed -$19M – 196
2018
Q2 		$19M Buy
281,600
+236,524
+525% +$13.2M 0.22% 81
2018
Q1 		$2.44M Buy
+45,076
New +$2.52M 0.03% 135

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PointState Capital's AERI Position: Q3 2018 in Review

PointState Capital sold out of Aerie Pharmaceuticals (AERI) in Q3 2018, closing a stake of 281,600 shares — an estimated $19M sold.

PointState Capital first reported a position in AERI in Q1 2018 and held it in 2 quarters. The position peaked at $19M in Q2 2018. 176 funds tracked by Wall St. Rank hold AERI as of Q3 2018.

  • PointState Capital reported no remaining Aerie Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • PointState Capital sold 281,600 Aerie Pharmaceuticals shares in Q3 2018, an estimated $19M.
  • PointState Capital first reported a position in Aerie Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • PointState Capital's Aerie Pharmaceuticals position peaked at $19M in Q2 2018.
  • 176 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2018.

Based on PointState Capital's 13F filing for Q3 2018, filed 14 Nov 2018.